Sun Sep 15 12:45:00 UTC 2024: ## Lantheus’ 177Lu-PNT2002 Shows Promise in Treating Advanced Prostate Cancer

**BEDFORD, Mass., Sept. 15, 2024 (GLOBE NEWSWIRE)** – Lantheus Holdings, Inc. (NASDAQ: LNTH) announced positive initial results from its SPLASH Phase 3 trial evaluating the efficacy of 177Lu-PNT2002, a novel radioligand therapy (RLT) for metastatic castration-resistant prostate cancer (mCRPC).

The study met its primary endpoint, demonstrating a significant improvement in radiographic progression-free survival (rPFS) for patients treated with 177Lu-PNT2002 compared to those receiving standard androgen receptor pathway inhibitors (ARPIs). Patients treated with 177Lu-PNT2002 experienced a median rPFS of 9.5 months, compared to 6.0 months for the ARPI group, representing a 29% reduction in the risk of disease progression or death.

Furthermore, the study showed that 177Lu-PNT2002 led to a statistically significant improvement in overall response rate (ORR), PSA50 reduction (a measure of tumor response), time to reduction of health-related quality of life (HRQoL) decline, and time to opioid use for cancer-related pain.

“These initial data underscore the importance of PSMA-targeted RLTs, including 177Lu-PNT2002, as potential treatment options for patients who have limited choices after progressing on ARPI therapy,” said Dr. Oliver Sartor, Director of Radiopharmaceutical Trials at the Mayo Clinic.

The safety profile of 177Lu-PNT2002 was deemed favorable compared to the ARPI group.

“We are encouraged by the initial results from the SPLASH trial, with 177Lu-PNT2002 demonstrating improvement in several key areas,” said Dr. Jeff Humphrey, Chief Medical Officer at Lantheus. “We are grateful to the patients and investigators who participated in this trial thereby helping to advance this important potential treatment option.”

Lantheus plans to continue monitoring the trial and expects to provide updates on overall survival data as they mature.

The SPLASH trial is ongoing and will continue to follow patients for up to 5 years from their first 177Lu-PNT2002 dose.

177Lu-PNT2002 has received Fast Track designation from the FDA for the treatment of mCRPC, a designation that aims to expedite the development and review of drugs to address unmet medical needs.

Read More